Why is Monopar Therapeutics stock down today? Key support levels to watch

Traders Union
All News
Stocks
Monopar Therapeutics slides 5.91% to $90.91

Highlights

MNPR/USD fell 5.91% to $90.915, closing near the session low in a high-volatility, bearish session.
The asset trades below key short- and medium-term moving averages but remains supported above its long-term trend line.
Indicators show strong selling pressure and a high probability of downside, with an expected range of $86.2796 to $95.5504 for coming sessions.

Bearish momentum holds as technical indicators signal persistent selling

MNPR/USD is currently trading below its MA-20 and MA-50, indicating short- and medium-term downside pressure. The stock remains above the MA-200, which defines the major support zone. The Ichimoku Kijun level sits at $98.98 and acts as the nearest overhead resistance. MACD and ADX readings highlight ongoing strong selling pressure, while RSI remains in oversold territory. Stoch RSI is overbought, CCI is neutral, and Bull/Bear Power also displays overbought conditions, pointing to minor intraday buying strength amid the dominant sell momentum. Price closed near the session’s low with a negative gap, signaling persistent volatility and reinforcing the bearish tilt reflected in momentum oscillators.

Further downside risk as volatility bands mark limited upside

For the next several sessions, the expected volatility band for MNPR ranges from $86.27 to $95.55. Upside probability is assessed as very low, while the probability of further downside is very high in the near term. The base scenario projects consolidation within this corridor, with a more likely bearish move emerging if the stock breaks below $86.27 support. Any meaningful bullish reversal would require a close above the key resistance at $98.98.

Anton Kharitonov, analyst at Traders Union, notes that Monopar Therapeutics is under pronounced technical pressure after the recent decline. He sees indicators confirming strong downside momentum, with support at $86.27 and resistance at $98.98. There is little evidence of any bullish catalyst, and price remains below short- and medium-term moving averages. "Until $86.27 breaks or a strong reversal appears, I remain cautious and do not expect meaningful upside in the near term."

Earlier, analysts noted that Monopar Therapeutics was exhibiting persistent short- and medium-term bearish momentum despite maintaining a long-term constructive trend. The current analysis reinforces this view, highlighting the importance of the $86.27 support as the critical level to watch for potential downside continuation in the near term.

Source of Data: MNPR Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.